Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

ABSTRACT: Introduction: Alzheimer's disease (AD) is a common, progressive neurological disorder whose incidence is reaching epidemic proportions. The prevailing "amyloid cascade hypothesis," which maintains that the aberrant proteolysis of beta-amyloid precursor protein (βAPP) into neurotoxic amyloid beta (Aβ) peptides is central to the etiopathology of AD, continues to dominate pharmacological approaches to the clinical management of this insidious disorder. This review is a compilation and update on current pharmacological strategies designed to down-regulate Aβ42 peptide generation in an effort to ameliorate the tragedy of AD. Areas covered: This review utilized online data searches at various open online-access websites including the Alzheimer Association, Alzheimer Research Forum; individ

SUBMITTER: Lukiw WJ 

PROVIDER: S-EPMC3399957 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature